Press Releases Arecor Therapeutics plc

Equities

AREC

GB00BMWLM973

Delayed London S.E. Other stock markets 12:20:50 13/06/2024 BST			5-day change	1st Jan Change
130 ^GBX	+1.96%		-18.24%	-28.77%

06-10	Political turmoil hits euro and banks	AN
06-10	Europe heads lower amid political turmoil in EU	AN

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

At278 Ultra-Concentrated Ultra-Rapid Acting Insulin Demonstrates Superiority in Phase i Clinical Trial in Overweight and Obese People With Type 2 Diabetes	05-20	AQ
Arecor Therapeutics reports strong 2023 results and outlines expanding product pipeline	05-17	AQ
Arecor and Medtronic Diabetes establish collaboration to develop a novel thermostable insulin for implantable pump delivery	05-09	AQ
Arecor Therapeutics announces collaboration on oral GLP-1 drug for diabetes and obesity treatment	03-14	AQ
ARECOR AND TRx BIOSCIENCES ESTABLISH RESEARCH COLLABORATION TO DEVELOP ORAL GLP-1 WITH ENHANCED BIOAVAILABILITY	03-12	AQ
Arecor Therapeutics reveals deal with "global medical products company"	12-05	AQ
Arecor Therapeutics takes major step with first commercial sale of AT220	11-17	AQ
First Product Incorporating Arecor’s Arestat Technology, At220, Launched in Europe	11-17	AQ
Arecor Therapeutics expecting a busy end to the year after solid first half progress	18/09/23	AQ
Arecor: Business Update	20/07/23	AQ
Arecor Therapeutics has "a strong basis to accelerate" growth strategy	24/04/23	AQ
Arecor Therapeutics gets second phase 1 trial for AT278 underway	27/03/23	AQ
Arecor Therapeutics "confident" in collaboration pipeline after another new deal	16/02/23	AQ
Arecor Therapeutics scientist hopeful that artificial pancreas "edging closer"	15/11/22	AQ
Arecor Therapeutics scientist hopeful that artificial pancreas 'edging closer'	15/11/22	EQ
Tetris Pharma Launches Ogluo® in Germany	01/11/22	BU
Headline results from Phase I clinical trial of ultra-rapid acting insulin candidate AT247 demonstrate significantly accelerated insulin absorption and early exposure compared to gold standard insulins NovoLog® and Fiasp®	11/10/22	AQ
BUSINESS UPDATE	14/07/22	AQ
ARECOR TO HOST KOL WEBINAR ON THE NEED FOR CONCENTRATED AND RAPID ACTING INSULIN TREATMENTS IN DIABETES CARE	18/05/22	AQ
ARECOR PRESENTS FULL DATA FROM POSITIVE PHASE I CLINICAL TRIAL OF AT278 ULTRA-CONCENTRATED ULTRA-RAPID ACTING INSULIN FOR DIABETES AT ATTD MEETING	28/04/22	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Arecor Therapeutics plc

Equities

AREC

GB00BMWLM973

Press Releases

Filters